BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29946194)

  • 1. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea.
    Lee DY; Yu JH; Park S; Han K; Kim NH; Yoo HJ; Choi KM; Baik SH; Kim NH; Seo JA
    Sci Rep; 2018 Jun; 8(1):9719. PubMed ID: 29946194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of fractures and diabetes medications: a nationwide cohort study.
    Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
    Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
    Koro CE; Bowlin SJ; Weiss SR
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
    Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
    Bowker SL; Lin M; Eurich DT; Johnson JA
    Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.